|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.01|
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) today announced that its subsidiary, Belgravia Dermatology Inc. (“Belgravia Dermatology”) has completed the selection of initial drug targets and biological markers for its pre-clinical work in cannabinoid based dermatological treatments for unmet medical needs. The Company’s indications of interest include acne, atopic dermatitis, and psoriasis. The initial focus of product development is acne.
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2018) - Mehdi Azodi, President & CEO of Belgravia Capital Inc. talks about the company's rapid growth phase that will benefit investors.If you cannot view the video above, please visit:http://www.b-tv.com/belgravia-ceo-clip-90sec/Belgravia Capital Inc.: (CSE: BLGV)Belgravia Capital International Inc. is focused on its three core business divisions: Incubation, Investments and also Royalties. Belgravia will also develop new companies with a focus on the legal medical cannabis industry. The incubation ...
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce that it has acquired 10.03% of the outstanding common shares of R&D Pharma Corp. (“RDP”). RDP is a Canadian corporation developing a vertically integrated medicinal cannabis business in Jamaica. Belgravia has acquired four million (4 million) common shares of RDP at a price of twenty-five (25) cents per share. Belgravia has the right to appoint an independent director to the Board of RDP. Mr. Kevin Strong, the Chief Financial Officer (“CFO”) of Belgravia, has been appointed CFO of RDP. The funding of the acquisition was by way of Canadian $500,000 (five-hundred thousand dollars) and 5,000,000 (five million) common shares of Belgravia.
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) today announced that it has completed the strategic transition of ICP Organics, the fully owned subsidiary of Belgravia, to a cannabinoid-based dermatology ethical drug research and product development company. Further, the name of ICP Organics, the dermatology division of Belgravia, is being changed to Belgravia Dermatology Inc. (“Belgravia Dermatology”).
TORONTO, April 27, 2018-- Belgravia Capital International Inc. is pleased to announce the results of the Company’ s Annual and Special Meeting of Shareholders held on April 26, 2018 in Toronto, Canada. ...
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division. Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America. The Company announced the appointment of Dr. Hanna on January 10, 2018, as Special Advisor to Belgravia’s wholly owned subsidiary, ICP Organics.